Stephane Wong
Overview
Explore the profile of Stephane Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahon F, Boquimpani C, Kim D, Benyamini N, Clementino N, Shuvaev V, et al.
Ann Intern Med
. 2018 Feb;
168(7):461-470.
PMID: 29459949
Background: Treatment-free remission (TFR)-that is, stopping tyrosine kinase inhibitor (TKI) therapy without loss of response-is an emerging treatment goal in chronic myeloid leukemia (CML). Objective: To evaluate TFR after discontinuation...
2.
Belloni B, Lambertini C, Nuciforo P, Phillips J, Bruening E, Wong S, et al.
J Clin Pathol
. 2012 Nov;
66(2):124-35.
PMID: 23125305
Unlabelled: Formalin fixation and paraffin embedding present the standard procedures for conserving clinical tissues for histological analysis. However, molecular analysis is impaired by the cross linking properties of formalin. The...
3.
OHare T, Zabriskie M, Eide C, Agarwal A, Adrian L, You H, et al.
Blood
. 2011 Sep;
118(19):5250-4.
PMID: 21908430
Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and...
4.
Wong S, Witte O
Annu Rev Immunol
. 2004 Mar;
22:247-306.
PMID: 15032571
The twenty-first century is beginning with a sharp turn in the field of cancer therapy. Molecular targeted therapies against specific oncogenic events are now possible. The BCR-ABL story represents a...
5.
Kharas M, Deane J, Wong S, OBosky K, Rosenberg N, Witte O, et al.
Blood
. 2004 Feb;
103(11):4268-75.
PMID: 14976048
BCR-ABL and v-ABL are oncogenic forms of the Abl tyrosine kinase that can cause leukemias in mice and humans. ABL oncogenes trigger multiple signaling pathways whose contribution to transformation varies...
6.
Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte O
Proc Natl Acad Sci U S A
. 2003 Sep;
100(20):11630-5.
PMID: 14500898
BCR-ABL expression led to a dramatic up-regulation of the IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptor beta common (IL-3Rbetac) and IL-3 receptor beta (IL-3Rbeta) chains in murine embryonic stem cell-derived...
7.
Wong S, McLaughlin J, Cheng D, Witte O
Blood
. 2003 Jan;
101(10):4088-97.
PMID: 12521991
Acute BCR-ABL expression during in vitro hematopoietic development of embryonic stem (ES) cells causes expansion of multipotent and myeloid progenitors with a concomitant reduction in differentiation toward erythroblasts. Progenitor cell...
8.
Le L, Kabarowski J, Wong S, Nguyen K, Gambhir S, Witte O
Cancer Cell
. 2002 Jun;
1(4):381-91.
PMID: 12086852
G2A is a lymphocyte-expressed G protein-coupled receptor whose genetic ablation results in the development of autoimmunity. Using HSV-TK reporter gene directed positron emission tomography (PET), we demonstrate that prior to...